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Abstract
Aim Haemorrhoids are a common condition, with nearly
30,000 procedures carried out in England in 2014/15, and
result in a significant quality-of-life burden to patients and
a financial burden to the healthcare system. This study
examined the cost effectiveness of haemorrhoidal artery
ligation (HAL) compared with rubber band ligation (RBL)
in the treatment of grade II–III haemorrhoids.
Method This analyses used data from the HubBLe study, a
multicentre, open-label, parallel group, randomised con-
trolled trial conducted in 17 acute UK hospitals between
September 2012 and August 2015. A full economic eval-
uation, including long-term cost effectiveness, was con-
ducted from the UK National Health Service (NHS)
perspective. Main outcomes included healthcare costs,
quality-adjusted life-years (QALYs) and recurrence. Cost-
effectiveness results were presented in terms of incre-
mental cost per QALY gained and cost per recurrence
avoided. Extrapolation analysis for 3 years beyond the trial
follow-up, two subgroup analyses (by grade of haemor-
rhoids and recurrence following RBL at baseline), and
various sensitivity analyses were undertaken.
Results In the primary base-case within-trial analysis, the
incremental total mean cost per patient for HAL compared
with RBL was £1027 (95% confidence interval [CI] £782–
£1272, p\ 0.001). The incremental QALYs were 0.01
QALYs (95% CI -0.02 to 0.04, p = 0.49). This generated
an incremental cost-effectiveness ratio (ICER) of £104,427
per QALY. In the extrapolation analysis, the estimated
probabilistic ICER was £21,798 per QALY. Results from
all subgroup and sensitivity analyses did not materially
change the base-case result.
Conclusions Under all assessed scenarios, the HAL pro-
cedure was not cost effective compared with RBL for the
treatment of grade II-III haemorrhoids at a cost-effective-
ness threshold of £20,000 per QALY; therefore, econom-
ically, its use in the NHS should be questioned.
Key Points for Decision Makers
Because of its significant high cost compared with
RBL, with very small additional health benefits, the
HAL procedure is unlikely to be cost effective for
the treatment of grade II–III haemorrhoids.
The long-term cost-effectiveness result is uncertain
due to the lack of good-quality evidence on long-
term recurrence, and therefore further research is
needed to resolve this issue.
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1 Introduction
Haemorrhoids are a common condition affecting as many as
one in three of the population [1], with nearly 30,000 pro-
cedures carried out in England in 2014/15 [2]. The degree of
symptoms and prolapse (protrusion of the haemorrhoids
outside the anal canal) are key determinants of the current
standard treatment choice, ranging from dietary advice to
rubber band ligation (RBL) in the outpatient department, to
an operation under general anaesthetic [3]. Although RBL is
cheap, it has a high reported recurrence rate and often needs
further procedure(s) to alleviate discomfort caused by
residual tissue, which may be repeat RBL or surgical inter-
vention such as excisional haemorrhoidectomy (EH) or a
stapled haemorrhoidopexy (SH).
Haemorrhoidal artery ligation (HAL) has been intro-
duced as an alternative treatment option. Although HAL
requires an anaesthetic, evidence suggests a recovery
similar to RBL but an effectiveness that approaches the
more intensive surgical options such as EH. Despite four
systematic reviews [4–7] and an overview by the UK
National Institute for Health and Care Excellence (NICE)
[8], there is a lack of good-quality data as evidence for the
advantages of the HAL; however, a recent trial (the Hub-
BLe trial) [9] comparing the effectiveness of HAL with
RBL goes some way to providing these data.
Using the data from HubBLe, we conducted a full eco-
nomic evaluation to establish the cost effectiveness of HAL
compared to RBL for the treatment of early-grade haemor-
rhoids. The headlines of the health economic analyses were
provided as part of the clinical effectiveness paper published
by Brown et al. [9]. The main trial results are described later
in this paper (see Sect. 2.2), which describes the methods
used for the economic evaluation and provides detailed
results for both trial-based and long-term cost effectiveness.
Methods used to undertake various subgroup analyses and
sensitivity analyses to address uncertainty associated with
the primary cost-effectiveness results are well-described and
their results are reported in this paper.
2 Methods
2.1 Overview
As recommended by the UK NICE [10], the economic
evaluation was undertaken from the National Health Ser-
vice (NHS) and Personal Social Services perspective for a
1-year time horizon (the trial follow-up). In the primary
within-trial analysis, cost effectiveness was expressed in
terms of incremental cost per quality-adjusted life-years
(QALY) gained. A secondary within-trial cost-effective-
ness analysis (CEA) was performed where the result is
expressed in terms of the incremental cost per recurrence
avoided. Long-term cost effectiveness was estimated by
extrapolating the analyses to a 4-year time horizon.
2.2 The HubBLe Trial
The HubBLe trial is a multicentre, open-label, parallel
group, randomised controlled trial (RCT) conducted in 17
acute UK hospitals from September 2012 to August 2015.
The study design, protocol, consort diagram and full clin-
ical effectiveness results have been published elsewhere
[9, 11]. In brief, the trial enrolled 372 patients with grade II
or early grade III haemorrhoids (piles that prolapse but
either spontaneously reduce or require minimal manual
replacement). Patients were randomly assigned to either the
HAL group (n = 185) or the RBL group (n = 187) and
followed for up to 12 months. The primary outcome of this
study was recurrence at 1-year post-procedure, which was
found to be 49% in the RBL group and 30% in the HAL
group (adjusted odds ratio 2.23, 95% confidence interval
[CI] 1.42–3.51, p = 0.0005). Data for health-related qual-
ity of life (HRQoL), resource use and clinical outcomes
used for CEAs come from the HubBLe trial. Table 1 shows
the clinical data inputs used in the analysis, including the
mean costs of each clinical event, standard deviation, and
sample size for both treatment groups. The clinical events
data include the procedures events, procedural and post-
procedural complications, hospital admissions, and medi-
cations on discharge.
2.3 Resource Use and Costs
The costing approach followed the standard stages used in
economic evaluation and involved identification of
resource use, measurement and valuation [12]. The use of
the following types of resources during RBL or HAL
procedures were identified and recorded: procedure event,
procedural and post-procedural complications, hospital
admissions, and medications on discharge. Post-discharge
resource use included outpatient treatments, surgical
treatments, emergency admissions, contact with healthcare
professions, follow-up treatments and procedures.
Data on measurement of resource use were collected in
HubBLe using the procedure details form completed on the
procedure day (day 0), clinical assessment form at
6 weeks, and consultant and general practitioner (GP)
questionnaires at 12 months. The participant questionnaire
at 1 year was also used as a sense-check for the consultant
and GP responses. All resource-use data collection forms
and questionnaires are provided as electronic supplemen-
tary materials (ESM) 1–5. For the HAL procedure, mea-
surements of resource use include the type of anaesthetic
(general and local, spinal, or sedation only), grade of
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operating surgeon, consultant supervision time, timing for
surgery and overall time spent in the operating theatre.
Types of hospital admissions were recoded and the length
of stay was measured based on the NHS average estimates
[13]. All visits to consultants, GPs and GP nurses were
recorded and resource use during each visit was calculated
using the average estimates based on the NHS [13] or
Personal Social Services Research Unit (PSSRU) of the
University of Kent approaches, where relevant [14].
Valuation of resource use followed different approaches
for procedure events and post-discharge events. A micro-
costing approach was applied for the HAL procedure event
as cost per minute in procedure, recovery time and theatre
overhead based on actual time spent during the procedure.
Unit costs for surgical kits used in the HAL procedure were
obtained from the NHS supply system. Unit costs for
resource use in 2014/15 prices were obtained, where rele-
vant, from routinely published national reference costs
sources. The NHS reference costs [13], the PSSRU’s report
on unit costs for health and social care [14] and the British
National Formulary (BNF) [15] were used. Other unit costs
were obtained from other sources, i.e. costs for the SH
procedure were obtained from McKenzie et al. [16] and
adjusted for inflation; blood transfusion costs were
obtained from the costing statement issued by NICE [17];
and costs for repeated RBL and HAL procedures were
calculated using average costs within HubBLe. All unit
costs are provided in Table 2. Discounting was not used for
trial-based analyses as it was carried out for a 1-year time
horizon.
2.4 Health Outcomes
QALY was used as an outcome measure for the primary
cost-utility analysis (CUA) as per NICE recommendations
[10]. The individual patient-level QALYs were calculated
using the 5-level version of the EuroQol 5-Dimension
HRQoL questionnaire (EQ-5D-5L) [18]. The utility scores
applied in calculating the QALYs were obtained using
recently published EQ-5D-5L tariffs based on the English
general public preferences [19]. The EQ-5D-5L measure-
ments used were taken in HubBLe at baseline, 1 day,
7 days, 21 days, 6 weeks and 12 months. Recurrence at
1 year was used as an outcome for a secondary CEA in
terms of additional cost per recurrence avoided.
2.5 Analysis
The economic evaluation involved CUAwithin the trial time
horizon as a primary analysis, whereas trial-based CEAwas
Table 1 Health services resource use and costs
RBL HAL
Mean costs (£) SD N (%)* Mean costs (£) SD N (%)*
Medications 2.04 8.4 187 (100) 7.59 8.4 185 (100)
RBL procedure 109.00 0.0 187 (100) 0.00 0.0 185 (100)
Excisional tag removal 0.00 0.0 187 (100) 10.02 31.6 185 (100)
HAL procedure 0.00 0.0 179 (96) 732.56 299.7 151 (82)
Admissions for surgery 0.00 0.0 187 (100) 23.01 80.5 158 (85)
Proctoscopy 5.02 5.5 149 (80) 4.71 5.5 140 (76)
Other elective procedure 0.00 0.0 187 (100) 7.23 98.4 185 (100)
Post-discharge admissions 41.73 253.0 150 (80) 65.66 314.9 143 (77)
Other procedures 0.00 0.0 150 (80) 0.76 9.1 143 (77)
Repeated RBL 82.45 276.3 187 (100) 32.05 148.0 185 (100)
Further HAL 203.76 587.6 187 (100) 18.72 179.6 185 (100)
Excisional haemorrhoidectomy 16.14 155.6 187 (100) 24.47 191.1 185 (100)
Stapled haemorrhoidopexy 26.51 255.6 187 (100) 0.00 0.0 185 (100)
RBL in the theatre 21.47 218.4 187 (100) 14.47 138.8 185 (100)
Admissions in 1 year 17.78 166.4 176 (94) 68.04 320.1 161 (87)
Emergency procedure 29.53 284.8 187 (100) 29.85 286.3 185 (100)
Consultant visits 88.59 131.2 175 (94) 86.39 151.2 161 (87)
GP visits 10.93 27.8 122 (65) 16.54 35.2 114 (62)
Nurse visits 0.56 6.2 122 (65) 0.85 3.8 113 (61)
RBL rubber band ligation, HAL haemorrhoidal artery ligation, SD standard deviation, GP general practitioner
* The numbers in parentheses represent the percentages of complete cases, as a proportion of the total number of patients randomised for each
treatment group, which were used for estimating the mean cost for each resource use item
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Table 2 Unit costs applied for valuation of resource use
Event Description Unit cost
(£)
Source Notes
RBL procedure
Procedure cost RBL procedure 109.00 NHS reference costs
2014/15 [13]
Outpatient procedure
Blood transfusion 170.14 NICE 2015 [17] Blood transfusion costing
statement
Hospital admission In-patient bed day 303.00 NHS reference costs
2014/15 [13]
–
Medication prescribed
post-procedure
Paracetamol 1.27 BNF 2015 [15] 500 mg, 32-tablet pack
Co-codamol 6.73 BNF 2015 [15] 30/500 mg, 100-tablet pack
Codeine 1.23 BNF 2015 [15] 15 mg, 28-tablet pack
NSAIDs 3.50 BNF 2015 [15] Ibuprofen 200 mg, 84-tablet
pack
Tramadol 14.10 BNF 2015 [15] 100 mg, 30-tablet pack
Laxative 3.82 BNF 2015 [15] Bisacodyl 5 mg, 100-tablet
pack
Antibiotic 5.03 BNF 2015 [15] Augmentin 375 mg,
21-tablet pack
HAL procedure
Anaesthetic General and local anaesthetic 100.08 NHS reference cost
2014/15 [13]
Spinal anaesthetic 200.00
HAL procedure Consultant cost per minute 2.30 PSSRU 2015 [14] Includes costs of
qualifications
Associate specialist cost per minute 2.13 PSSRU 2015 [14] Includes costs of
qualifications
Surgical trainee cost per minute 2.13 PSSRU 2015 [14] Includes costs of
qualifications
Fellow cost per minute 2.13 PSSRU 2015 [14] Includes costs of
qualifications
Specialist nurse cost per minute 1.52 PSSRU 2015 [14] Includes costs of
qualifications
Research nurse cost per minute 1.52 PSSRU 2015 [14] Includes costs of
qualifications
Registrar cost per minute 1.20 PSSRU 2015 [14] Includes costs of
qualifications
Scrub nurse cost per minute 1.52 PSSRU 2015 [14] Includes costs of
qualifications
Cost per minute in recovery 0.41 McKenzie et al., 2009 [16] Adjusted for inflation
Cost per minute for theatre overheads 13.74 McKenzie et al., 2009 [16] Adjusted for inflation
Operating event Outpatient procedure 109.00 PSSRU 2015 [14]
Surgical kit for the HAL procedure 432.00 NHS supply system
Excision of skin tags 109.00 NHS reference costs
2014/15 [13]
Outpatient procedure
Procedure cost Cost of HAL surgery (used in
sensitivity analysis)
1128.00 NHS reference costs
2014/15 [13]
Intermediate anal procedure
(FZ22B (EL)
Hospital admission Inpatient bed day 303.00 NHS reference costs
2014/15 [13]
Need for blood transfusion 170.14 NICE 2015 [17] Blood transfusion costing
statement
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conducted as a secondary analyses. A long-term CUA was
conducted by extrapolating the primary analysis to a 4-year
time horizon. All analyses involved differences in costs and
outcomes (QALYs and recurrence at 1 year, respectively).
Analyses of trial data were undertaken using Stata version
13.1 (StataCorp LLC, College Station, TX, USA).
The base-case primary analysis was based on imputed
data. The Multiple Imputation Chained Equations (MICE)
method with predictive mean matching was used for
imputing missing values of costs, QALYs and baseline
utilities [20, 21]. Age, sex, grade of haemorrhoids, centre
and randomisation group were used as imputation variables
Table 2 continued
Event Description Unit cost
(£)
Source Notes
Medication on discharge Paracetamol 1.27 BNF 2015 [15] 500 mg, 32-tablet pack
Co-codamol 6.73 BNF 2015 [15] 30/500 mg, 100-tablet pack
Codeine 1.23 BNF 2015 [15] 15 mg, 28-tablet pack
NSAIDs 3.50 BNF 2015 [15] Ibuprofen 200 mg, 84-tablet
pack
Tramadol 14.10 BNF 2015 [15] 100 mg, 30-tablet pack
Laxative 3.82 BNF 2015 [15] Bisacodyl 5 mg, 100-tablet
pack
Antibiotic 5.03 BNF 2015 [15] Augmentin 375 mg,
21-tablet pack
GTN paste 39.30 BNF 2015 [15] GTN ointment 0.4%, 30 g
Diltiazem paste 73.83 BNF 2015 [15] 2% diltiazem cream
Post-discharge (RBL or HAL)
Outpatient treatment Outpatient visit 114.00 NHS reference costs
2014/15 [13]
Injection sclerotherapy 4.79 BNF 2015 [15] Phenol 5% injection 5-ml
amp
Excisional haemorrhoidectomy 1508.72 NHS reference costs
2014/15 [13]
FZ22E (EL)
Stapled haemorrhoidopexy 2478.42 McKenzie et al., 2009 [16] Adjusted for inflation
Rubber band ligation (in theatre) 1338.45 NHS reference costs
2014/15 [13]
FZ22E (EL)
Other elective procedure 1338.45 NHS reference costs
2014/15 [13]
FZ23A
Emergency admissions Emergency admission for symptoms
related to RBL/HAL
1565.00 NHS reference costs
2014/15 [13]
NEL
Blood transfusion 170.14 NICE 2015 [17] Blood transfusion costing
statement
Emergency operation 2761.00 NHS reference costs
2014/15 [13]
FZ23A
Contact with health
professionals
GP visit 46.00 PSSRU 2015 [14]
Nurse visit (GP practice) 13.70 PSSRU 2015 [14] Based on 15.5 min per visit
Consultant visit 114.00 NHS reference costs
2014/15 [13]
Further treatments GTN paste 39.30 BNF 2015 [15] GTN ointment 0.4%, 30 g
Diltiazem paste 73.83 BNF 2015 [15] 2% diltiazem cream
Recurrence treatment costs Proctoscopy at 6-week assessments 10.99
RBL after recurrence 523.16 Mean RBL cost within the
HubBLe trial
Admissions with complications 1565.00 NHS reference costs
2014/15 [13]
NEL
RBL rubber band ligation, HAL haemorrhoidal artery ligation. NSAIDs nonsteroidal anti-inflammatory drugs, NHS National Health Service,
NICE National Institute for Health and Care Excellence, BNF British National Formulary, PSSRU Personal Social Services Research Unit, GP
general practitioner, GTN glyceryl trinitrate, EL elective, NEL non-elective
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in the imputation model. A seemingly unrelated regression
(SUR) model was fitted for estimating differential mean
total costs and QALYs between HAL and RBL [22]. The
SUR model assumes normal distribution for both costs and
QALYs. It was controlled for imbalance in baseline utility
at the QALY equation [23], and took into account the
correlation between costs and QALYs [22]. The incre-
mental cost-effectiveness ratio (ICER) was estimated from
the SUR regression results, which gives the cost per
additional QALY gained. To assess cost effectiveness, the
estimated ICER was then compared with the NICE cost-
effectiveness threshold of £20,000–30,000 per QALY [10].
Another advantage for using the SUR model was that it
provided the estimation of the full variance–covariance
matrix, which was used for addressing uncertainty, as
described in the next paragraph.
Uncertainty around the primary CUA estimates was
addressed using a number of approaches based on the
parametric method [24, 25]. Five key parameters from the
SUR regression output were used for conducting a fully
parametric analysis. These parameters were difference in
mean costs, standard error of differential mean costs, dif-
ference in mean QALYs, standard error of differential
QALYs, and covariance between costs and QALYs. From
these parameters, the cost-effectiveness acceptability curve
(CEAC) was produced. The higher bound of the NICE
cost-effectiveness threshold of £30,000 per QALY was
used as the standard decision rule in these analyses. The
cost-effectiveness threshold was then varied from £0 to
£140,000 to address uncertainty across different levels of
willingness to pay.
A subgroup analysis was conducted for patients with
new haemorrhoids and patients with recurrence following
RBL at baseline (those who had a previous unsuccessful
RBL procedure). An additional regression analysis was
conducted by controlling for the grade of haemorrhoids (II/
III) on both cost and QALY equations, together with
baseline utility within the SUR model. The latter analysis
allowed us to assess the effect of the grade of haemorrhoids
on the ICER estimate, and hence on cost-effectiveness. A
secondary CEA was conducted for estimating the addi-
tional cost per recurrence avoided.
A number of sensitivity analyses were performed to
assess the robustness of estimates from the base-case
analysis. Three scenarios were considered. First, a CUA
using complete cases only was carried out, and, second,
analysis using the NHS reference cost for the HAL pro-
cedure rather than the micro-costing approach described
earlier was carried out. In this analysis, HAL was consid-
ered as a day case intermediate anal procedure and the
national average cost associated with this Health Resource
Group (HRG) was applied [13]. A third scenario assumed
QALY losses for each subsequent procedure performed
during the trial follow-up. Since the EQ-5D-5L question-
naire was completed at particular follow-up time points
that did not coincide with any subsequent procedure, esti-
mated QALY decrements were applied. QALY decrements
for subsequent HAL or RBL procedures were estimated
using mean utility scores from the HubBLe trial measured
at baseline and days 1 and 7. For EH and SH, utility
decrements were taken from a published UK study [26].
A secondary analysis explored the extrapolation beyond
the trial time horizon for estimating the long-term cost
effectiveness. Costs, utilities and recurrence data collected
within the HubBLe trial were used in combination with
external evidence [3, 27] on long-term recurrence for
analyses over a 4-year time horizon. The choice of time
horizon was driven by evidence from the external studies
where recurrence rates for both HAL and RBL were
available over this time horizon.
A three-health-state Markov model was constructed for
extrapolating within-trial analysis to long-term cost effec-
tiveness. To maintain consistency with the trial analyses,
health states were chosen based on the primary outcome
measure of the HubBLe trial, i.e. recurrence. Health states
modelled were new haemorrhoids, recurrence and no
recurrence. Patient transition from the recurrence or no
recurrence health states to new haemorrhoids was restricted
in the model, assuming that any new haemorrhoids after
the first year is not associated with condition at baseline.
The UK Treasury discount rate of 3.5% per year was used
for discounting all future costs and QALYs to their present
values [10]. A probabilistic sensitivity analysis (PSA) was
run on 1000 Monte Carlo simulations to address uncer-
tainty around the model parameters. The main parameters
used in the PSA analysis over 4 years were based on the
deterministic analysis, and their values were as follows.
For RBL, the mean total cost was £1205 (standard error
[SE] = 351), and the mean QALY was 3.48 (SE = 0.20).
For HAL, the mean total cost was £2322 (SE = 848), and
the mean QALYs was 3.53 (SE = 0.25). Normal distri-
bution was assumed for both costs and QALYs in the
extrapolation PSA to maintain consistency with the within-
trial analysis. The transition probabilities deriving patients’
movement between the modelled health states is provided
as ESM 6.
3 Results
3.1 Healthcare Costs
The mean total healthcare costs per patient, and 95% CIs,
are reported as descriptive statistics based on the complete
case analysis. For the RBL group, the mean total cost per
patient was £709 (n = 103, 95% CI £522–£896), and for
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the HAL group, the mean total cost was £1767 (n = 99,
95% CI £5568–£1965). Within-trial cost data were right
skewed, with only a few patients incurring very high costs
in both arms of the trial.
3.2 Health-Related Quality of Life
The mean baseline utilities and QALYs for RBL and HAL
are descriptively reported based on complete case analysis.
The mean baseline EQ-5D-5L utility score was 0.90
(n = 149, 95% CI 0.88–0.92) in the RBL group and 0.89
(n = 152, 95% CI 0.87–0.92) in the HAL group. The mean
QALYs for the RBL group was 0.91 (n = 85, 95% CI
0.89–0.94), and 0.92 (n = 92, 95% CI 0.90–0.95) for the
HAL group.
3.3 Trial-Based Cost Effectiveness
The primary base-case cost-effectiveness results, together
with results from all subgroup analyses and sensitivity
analyses, are presented in Table 3. In the primary base-case
analysis, the incremental total mean cost per patient for
HAL compared with RBL over a 1-year time horizon was
£1027 (95% CI £782–£1272, p\ 0.001). The adjusted
estimates of differential QALYs, after controlling for
imbalance in baseline utility, showed that HAL gained an
average of 0.01 QALYs (95% CI -0.02 to 0.04), although
the difference was not statistically significant (p = 0.49).
This generated an ICER of £104,427 per QALY, suggest-
ing that HAL is highly unlikely to be cost effective at the
£20,000–30,000 threshold. The cost per recurrence avoided
was estimated to be £4882 (95% CI £3628–£6135).
The CEAC generated from the parametric analysis
applied on imputed data is presented in Fig. 1. This graph
shows the probability that HAL is cost effective under a
range of cost-effectiveness threshold values (£0–
£140,000). At £20,000 per QALY threshold, HAL had zero
probability of being cost effective; at the £30,000 thresh-
old, it had a 0.05 probability of cost effectiveness.
3.4 Subgroup and Sensitivity Analyses
Results from subgroup analysis for patients with recurrence
following RBL (at baseline) led to an ICER of £246,959
per QALY, suggesting that QALY gains were more costly
for this group compared with new patients (£89,972 per
QALY). This result was driven by the smaller difference in
QALYs for patients with recurrence following RBL at
baseline (Table 3). The second subgroup analysis condi-
tional on patients with grade III haemorrhoids (at baseline)
generated an ICER of £108,478 per QALY after adjusting
for baseline grade of haemorrhoids.
Results from all sensitivity analyses are reported in
Table 3. These did not materially change the base-case
result and HAL remained non-cost-effective in all scenar-
ios. The first sensitivity analysis based on complete cases
led to an ICER of £90,688 per QALY. The second sensi-
tivity analysis, based on using the NHS reference cost for
HAL, generated an ICER of £152,479 per QALY. Finally,
the third analysis, which accounted for QALY decrements
Table 3 Cost-effectiveness results for base–base, subgroup and sensitivity analyses
Analysis Incremental cost [£]:
HAL–RBL (95% CI);
p value
Incremental QALYs: HAL–
RBL (95% CI); p value
ICER £
per QALY
gained
Probability that HAL is cost
effective at the threshold
20,000/QALY (£30,000/
QALY)
Base-case analysis: trial based
analysis based on imputed data
1027 (782–1272);\0.001 0.01 (-0.02 to 0.04); 0.49 104,427 0.00 (0.05)
Subgroup analysis: patient with
recurrence following RBL at
baseline
1091 (623–1558);\0.001 0.004 (-0.049 to 0.058);
0.87
246,959 0.05 (0.13)
Subgroup analysis: patient with
grade III haemorrhoids
999 (760–1239);\0.001 0.01 (-0.09 to 0.037); 0.52 108,478 0.00 (0.07)
Sensitivity analysis: complete case
analysis
1073 (700–1447);\0.001 0.01 (-0.019 to 0.04); 0.50 90,688 0.00 (0.00)
Sensitivity analysis: using the
NHS reference cost for HAL
1498 (1262 –
1735);\0.001
0.01 (-0.018 to 0.038); 0.49 152,479 0.00 (0.00)
Sensitivity analysis: applying
QALY decrements for
subsequent procedures
1030 (760–1300);\0.001 0.01 (-0.02 to 0.036); 0.56 125,076 0.00 (0.05)
Long-term extrapolation analysis 1125 (1117–1133) 0.05 (0.048–0.055) 21,798 0.66 (0.78)
HAL haemorrhoidal artery ligation, RBL rubber band ligation, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, CI
confidence interval, NHS National Health Service
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for subsequent procedures, had an ICER estimate of
£125,076 per QALY.
3.5 Long-Term Cost Effectiveness
In the extrapolation analysis, the estimated cost per QALY
for HAL compared with RBL for a 4-year time horizon was
lower compared with the analysis within the trial. The
probabilistic ICER was estimated at £21,798 per QALY,
produced from an incremental total mean cost of £1125
(95% CI £1117–£1133) and incremental mean QALYs of
0.05 (95% CI 0.048–0.055). Figure 2 shows the CEAC
based on 1000 PSA simulations from the extrapolation
analysis. The PSA revealed that HAL has a 0.66
probability of being cost effective at the £20,000 threshold
when long-term cost effectiveness was considered. At the
30,000 threshold, HAL has a 0.78 probability of being
cost effective.
4 Discussion
The main findings of the within-trial analysis of this study
suggest that the HAL procedure is highly unlikely to be
cost effective compared with RBL under the cost-effec-
tiveness threshold of £20,000–£30,000 per QALY. In the
base-case trial-based CUA, HAL was £1027 more costly
compared with RBL, and the additional health benefit
generated was very small (0.01 QALYs). The incremental
total mean cost per QALY was £104,427. All sensitivity
analyses did not materially change the base-case results
and HAL remained non-cost-effective in all scenarios,
indicating the robustness of the primary base-case analysis.
When different population subgroups were considered,
analysis of patients with recurrence following RBL (at
baseline), as well as new patients, was broadly consistent
with the overall study population, although the incremental
cost per QALY was higher for patients with recurrence
compared with new patients (£246,959 compared with
£89,972). Similarly, results from another subgroup analysis
based on the grade of haemorrhoids (II/III) generated fairly
similar cost-effectiveness results.
Trial-based cost effectiveness in terms of additional cost
per recurrence avoided was estimated at £4882. This
indicates that HAL could only be considered as worthwhile
Fig. 1 Cost-effectiveness acceptability curve showing the probability
that HAL is cost-effectiveness at different thresholds (within trial
analysis)
Fig. 2 Cost-effectiveness
acceptability curve showing the
probability that HAL is cost-
effectiveness at different
thresholds (extrapolation
analysis)
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economically if the healthcare system is willing to pay
approximately £5000 per each case of recurrence avoided
as a result of introducing the HAL procedure. However,
this approach is not generally used within the NICE deci-
sion-making framework, where cost per QALY is the
preferred measure used to establish cost effectiveness. The
long-term cost effectiveness generated from extrapolating
the analyses beyond the trial time horizon suggested a
lower cost per QALY compared with the short-term trial-
based analyses. The probability of HAL cost effectiveness
remained low at the £20,000 threshold based on the
extrapolation analysis (but more likely than the within–trial
analysis).
Additional evidence on healthcare cost from the litera-
ture is sparse for this condition. Cost analysis is available
in one trial comparing SH with RBL for the treatment of
grade II haemorrhoids [16]. The results from this study are
consistent with the findings in HubBLe. The mean total
cost for RBL was estimated at £273 with the difference in
mean total cost of SH versus RBL being substantially
higher (£1483), generated negative difference in QALYs
(-0.014), and SH was unlikely to be cost effective com-
pared with RBL at a 1-year time horizon [16]. Interest-
ingly, the study found that RBL was associated with a
higher recurrence rate compared with SH, with an esti-
mated additional cost of £4945 per recurrence avoided.
Another multicentre RCT comparing HAL with SH has
estimated the incremental cost per averted complication at
€7192 [28]. The study concluded that HAL was more
expensive, was a lengthy procedure, and provided inferior
outcomes, suggesting an increased risk of recurrence [28].
Among the strengths of this study is that it is based on a
pragmatic, multicentre RCT design using a mix of teaching
and district general hospitals across the UK, ensuring that
the results could be generalisable to all patient populations
seeking treatment for grade II/III haemorrhoids. The
numbers of patients recruited are such that there can be
considerable confidence in the conclusions drawn from the
trial-based cost-effectiveness analyses. We used a three-
pronged approach for resource use data collection within
the trial, which was based on hospital records (procedure
form, clinical assessment form, and consultant 1-year
questionnaire), GP records (GP 1-year questionnaire), and
patient self-reported 1-year questionnaire. The latter was
used as a sense check for hospital and GP records, which
might be expected as rather more complete. This approach
would limit the impact of recall bias because patient-re-
ported data were largely secondary.
The main limitation of this study is that the long-term
cost-effectiveness result is subject to uncertainty. This
should be interpreted with caution due to uncertainty
around long-term recurrence rates emanating from the poor
quality of external evidence used in the extrapolation
model. However, the findings of this study add to the
growing body of evidence base that proposes various
interventions for management of grade II–III haemor-
rhoids. Among this, the HubBLe and eTHoS trials [9, 29]
include four interventions for this patient population: RBL,
HAL, SH and EH. Pooling of data from these studies with
existing datasets [30] in a network meta-analysis should be
considered. This will allow comparison of all four principal
procedures and provide robust cost-effectiveness evidence
to inform treatment guidelines.
5 Conclusions
Based on all scenarios assessed in this study, the HAL
procedure is unlikely to be cost effective compared with
RBL for the treatment of grade II–III haemorrhoids;
therefore, from an economic perspective, its use for these
particular patients should be questioned.
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